Sign Out
JANUMET (sitagliptin phosphate/metformin HCl) is contraindicated in patients with: Severe renal impairment (eGFR <30 mL/min/1.73 m2) (see Monitoring of renal function under Precautions).
Known hypersensitivity to sitagliptin phosphate, metformin hydrochloride or any other component of JANUMET (see Sitagliptin phosphate: Hypersensitivity Reactions under Precautions and Postmarketing Experience under Side Effects).
Acute or chronic metabolic acidosis, including lactic acidosis, diabetic ketoacidosis, with or without coma.
JANUMET should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see Metformin hydrochloride under Precautions).
